Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
The two Hep C drugs are similar enough chemically to warrant caution.
Gilead posted strong second-quarter earnings and is moving ahead aggressively with its new hepatitis C drugs.
Valuation shorts can be investment quicksand, explains TheStreet columnist Nate Sadeghi.
TheStreet contributor Nate Sadeghi calls for healthcare investors to start acting like owners.
With a second cancer drug approval looming, Onyx can join a select group of successful and profitable biotech companies.
TheStreet's Nathan Sadeghi-Nejad examines which health care stocks benefit from the Supreme Court's decision to uphold health care reform.
Advice to lorcaserin bulls: Cherish the moment but sell Arena, says TheStreet contributor Nate Sadeghi.
An undervalued stock could move higher if Alkermes continues to grow through acquisitions.
Six possible outcomes of the Court's healthcare ruling and what it means for healthcare stocks.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.